AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17225939
Drug: High-dose radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiation therapy (6.0 Gy total, 1.0 Gy per fraction, 2 fractions per week for 3 weeks)
Trial: 17225939
Drug: Low-dose radiation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiation therapy (3.0 Gy total, 0.5 Gy per fraction, 2 fractions per week)
Trial: 30005744
Drug: Midodrine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (2.5 mg twice a day)
Trial: 30005744
Drug: Pyridostigmine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (30 mg twice a day)
Trial: 30005744
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of midodrine and pyridostigmine
Trial: 25007091
Drug: pSG2.HIVconsv DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pSG2.HIVconsv DNA vaccine
Trial: 25007091
Drug: ChAdV63.HIVconsv vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdV63.HIVconsv vaccine
Trial: 25007091
Drug: MVA.HIVconsv vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA.HIVconsv vaccine
Trial: 19931416
Drug: IRSCE at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRSCE at 14.0 g (7.8 g of inulin)
Trial: 19931416
Drug: IRSCE at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRSCE at 8.1 g/d (5.0 g of inulin)
Trial: 19931416
Drug: Control (sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (sucrose 10 g and 8.1 g/d)
Trial: 10720834
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate
Trial: 11494545
Drug: IFN-ribavirin combination
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IFN-ribavirin combination therapy
Trial: 11494545
Drug: IFN monotherapy
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN monotherapy
Trial: 9470077
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (SB) 400 micrograms every 4 hours
Trial: 9470077
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol (SM) 100 micrograms every 12 hours
Trial: 31361019
Drug: NKTR-181 (100-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-181 (100-600 mg BID)
Trial: 28784179
Drug: Social skills
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social skills training (n=10 CCS), bi-weekly sessions over 8 months covering making social contacts, problem solving, emotional self-regulation, emotional expression and recognition.
Trial: 25488448
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficient (<12 ng/ml)
Trial: 25488448
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D insufficient (12 to <20 ng/ml)
Trial: 25488448
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D sufficient (≥ 20 ng/ml)
Trial: 19323613
Drug: Cyclobenzaprine ER
RxNorm normalized name: cyclobenzaprine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine ER 30 mg
Trial: 19323613
Drug: Cyclobenzaprine ER
RxNorm normalized name: cyclobenzaprine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine ER 15 mg
Trial: 19323613
Drug: Cyclobenzaprine immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine immediate release (CIR) 10 mg
Trial: 11304861
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of estriol (1 mg/d) and pelvic floor muscle exercise (PFME)
Trial: 3115138
Drug: Intrathecal buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal buprenorphine (0.15 mg) plus 20 mg tetracaine
Trial: 3115138
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (20 mg tetracaine only)
Trial: 28736918
Drug: Erenumab (AMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab (AMG 334), single doses ranging from 1 mg to 70 mg
Trial: 28736918
Drug: Erenumab (AMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab (AMG 334), multiple doses
Trial: 25832556
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding (n=44)
Trial: 25832556
Drug: Late oral
RxNorm normalized name: Adalate Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late oral feeding (n=45)
Trial: 24834772
Drug: SIT (Allergen-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIT (Allergen-specific immunotherapy)
Trial: 9355902
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment (Control)
Trial: 22808958
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (40 children)
Trial: 2125547
Drug: Fluvoxamine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (starting at 50 mg for 3 days, increasing to 100 mg for 3 days, then up to 150 mg daily if necessary)
Trial: 2125547
Drug: Imipramine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (starting at 50 mg for 3 days, increasing to 100 mg for 3 days, then up to 150 mg daily if necessary)
Trial: 19190104
Drug: Continuous sc
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous sc insulin and pramlintide infusion (part B)
Trial: 19190104
Drug: Continuous sc
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous sc insulin monotherapy (part A)
Trial: 9726693
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dexibuprofen
Trial: 9726693
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg dexibuprofen
Trial: 9726693
Drug: Both dexibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both dexibuprofen preparations
Trial: 30260294
Drug: JNJ-54175446 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-54175446 (doses ranging from 0.5 to 600 mg)
Trial: 27455573
Drug: Remaxol (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remaxol (single daily intravenous administration, 400 mL at 3-4 mL/min rate) for 3-5 days after thrombolytic therapy
Trial: 27455573
Drug: Conventional thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional thrombolytic therapy
Trial: 25514391
Drug: Low glycemic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low glycemic index multi-nutrient supplement (breakfast replacement)
Trial: 20123859
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention (before CPAP therapy)
Trial: 20123859
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) therapy after 3 months
Trial: 18590203
Drug: tijiaseluo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tijiaseluo (6 mg, qd)
Trial: 19589241
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg/day)
Trial: 9589245
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 mg/day)
Trial: 15716710
Drug: Combined (losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined (losartan 50 mg/day plus ramipril 5 mg/day)
Trial: 15716710
Drug: Hydrochlorothiazide (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (12.5 mg/day) added as needed
Trial: 8721801
Drug: Demographic variables
RxNorm normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demographic variables (e.g., being male, not having medical insurance)
Trial: 8721801
Drug: Health beliefs
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health beliefs (e.g., extra beats are harmful, a higher degree of general health concern)
Trial: 1918659
Drug: Lithium discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium discontinuation
Trial: 1918659
Drug: Inositol administration
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol administration
Trial: 7071805
Drug: Subcutaneous calcium
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous calcium heparin (5,000 units eight-hourly)
Trial: 7071805
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin monitored by maintaining the standardised APTT at 50 secs
Trial: 31215471
Drug: Surgical excision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical excision of the keloid scar followed by sub-dermal injection of triamcinolone acetonide (2 ampules of 10 mg/1 ml each) at the time of wound closure.
Trial: 31215471
Drug: Surgical excision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical excision of the keloid scar without corticosteroid injection (control group).
Trial: 23497336
Drug: Eltrombopag 75
RxNorm normalized name: eltrombopag 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 75 mg daily
Trial: 8544782
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin infusion (5, 10, 20 mU . m-2 . min-1)
Trial: 8544782
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin infusion (40, 80, 160 mU . m-2 . min-1)
Trial: 31283555
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care (no acupuncture treatment)
Trial: 25623520
Drug: Mud-bath therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud-bath therapy (12 mudpacks and 12 thermal baths) with continued TNF inhibitor treatment
Trial: 25623520
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy alone (TNF inhibitors)
Trial: 24964805
Drug: Quadrivalent meningococcal
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent meningococcal conjugate vaccine
Trial: 24964805
Drug: Quadrivalent meningococcal
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent meningococcal polysaccharide vaccine
Trial: 17312228
Drug: PCEA+AMB (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA+AMB (n = 21, 0.1% ropivacaine + fentanyl 2 microg/mL, bolus 5 mL, lockout 10 min, basal automated boluses of 5 mL/h)
Trial: 17312228
Drug: PCEA+BCI (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA+BCI (n = 21, 0.1% ropivacaine + fentanyl 2 microg/mL, bolus 5 mL, lockout 10 min, basal infusion 5 mL/h)
Trial: 15211441
Drug: n-3 Polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 Polyunsaturated fatty acids (PUFAs) 2.4 g for 8 weeks
Trial: 10696320
Drug: Tropicamide 1%
RxNorm normalized name: TROPICAMIDE 1% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropicamide 1% spray
Trial: 9156934
Drug: Epsilon-aminocaproic acid
RxNorm normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon-aminocaproic acid (EACA) given in a daily dose of 85-230 mg/kg for 1-11 days
Trial: 26976495
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no caffeine treatment)
Trial: 20222114
Drug: Ultrasound-guided corticosteroid
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided corticosteroid injection
Trial: 16175189
Drug: Irinotecan (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (110 mg/m² on day 1 and 100 mg/m² on day 8) plus cisplatin (80 mg/m² on day 8)
Trial: 16175189
Drug: Cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (80 mg/m² on day 1)
Trial: 1417429
Drug: Imipramine hydrochloride
RxNorm normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine hydrochloride tricyclic pharmacotherapy
Trial: 1417429
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy and pharmacotherapy combined
Trial: 4043659
Drug: Ursodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid, 1000 mg/day for 1 month
Trial: 27530375
Drug: Ingenol mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol mebutate gel (IMB) - 3 days treatment cycle
Trial: 27530375
Drug: Daylight photodynamic
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daylight photodynamic therapy (dlPDT) - single session
Trial: 23983039
Drug: TCZ‐SC (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCZ‐SC (subcutaneous tocilizumab) 162 mg every 2 weeks
Trial: 23983039
Drug: TCZ‐IV (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCZ‐IV (intravenous tocilizumab) 8 mg/kg every 4 weeks
Trial: 12640021
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose recombinant human IL-6 (HiIL-6; n = 6)
Trial: 12640021
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose IL-6 (LoIL-6; n = 6)
Trial: 10232639
Drug: Lactulose (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (25 g)
Trial: 10232639
Drug: Fructooligosaccharides (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructooligosaccharides (25 g)
Trial: 3121350
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg orally after 90 min of insulin infusion)
Trial: 21367594
Drug: Indacaterol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol 150 μg once-daily
Trial: 23490225
Drug: Formoterol 12
RxNorm normalized name: formoterol 12 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 12 μg twice-daily
Trial: 19541503
Drug: Oral unsaturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral unsaturated fat supplements (90mL of Calogen and 4 capsules of Pikasol)
Trial: 16885013
Drug: CHF3381 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF3381 (500 mg)
Trial: 12131110
Drug: Gabapentin (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1,200 mg)
Trial: 8154645
Drug: Cholesterol levels
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol levels lower than 4.14 mmol/L (160 mg/dL)
Trial: 2680584
Drug: Theophylline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (6 mg.kg‐1)
Trial: 2680584
Drug: PAF (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAF (inhaled in five successive doses every 15 min)
Trial: 769707
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg D(-)penicillamine daily
Trial: 769707
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg D(-)penicillamine daily
Trial: 769707
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of therapy
Trial: 769707
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg and 1200 mg D(-)penicillamine
Trial: 29122262
Drug: Geranium aroma
RxNorm normalized name: ADENOSINE 0.012 g in 30 g TOPICAL PATCH [LOVELY GERANIUM AROMATHERAPY MASK 30g]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geranium aroma (3 drops of geranium essential oil inhaled for 20 minutes a day for 2 days)
Trial: 29122262
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 drops of placebo inhaled for 20 minutes a day for 2 days)
Trial: 23684411
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg once every 12 weeks
Trial: 23684411
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg once every 4 weeks
Trial: 12544691
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lansoprazole twice daily with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week
Trial: 12544691
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rabeprazole twice daily with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week
Trial: 12544691
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg rabeprazole twice daily with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week
Trial: 25373361
Drug: bFGF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bFGF treatment (0.2-0.25 mL of bFGF solution applied directly onto the TM once daily until closure)
Trial: 25373361
Drug: bFGF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bFGF treatment (subgroup D, applied after 3 days post-injury)
Trial: 25373361
Drug: bFGF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bFGF treatment (subgroup C and D)
Trial: 17449934
Drug: Nadroparin (7,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (7,500 U, twice daily)
Trial: 17449934
Drug: Coumarin derivatives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coumarin derivatives with aspirin
Trial: 7651639
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate therapy
Trial: 7651639
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate therapy with ethinyl E2 supplementation
Trial: 27916207
Drug: Insulin-supplemented medium
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-supplemented medium
Trial: 23895188
Drug: Birth Preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birth Preparation Programme (BPP)
Trial: 15947280
Drug: Montelukast (cysteinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (cysteinyl leukotriene antagonist)
Trial: 15947280
Drug: Loratadine (antihistamine)
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine (antihistamine)
Trial: 15970290
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg/day for 6 months)
Trial: 2129822
Drug: Ispaghula therapy
RxNorm normalized name: ISPAGHULA
DrugBank: Plantago ovata seed (DB14585)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ispaghula therapy
Trial: 28390770
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of concentrated bone marrow aspirate (cBMA) via MarrowStim
Trial: 25881966
Drug: levofloxacin/bismuth therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levofloxacin/bismuth therapy
Trial: 25881966
Drug: BMT quadruple
RxNorm normalized name: BMT IM
DrugBank: Biomodulin T (DB16529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMT quadruple therapy
Trial: 19482764
Drug: Light-protected parenteral
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-protected parenteral nutrition (n = 428)
Trial: 19482764
Drug: Light-exposed parenteral
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-exposed parenteral nutrition (n = 438)
Trial: 11182041
Drug: Paclitaxel (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (135 mg/m2, 3 h) and Carboplatin (AUC 4-5)
Trial: 9391999
Drug: Oral trimegestone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trimegestone, 0.10 mg/day
Trial: 9391999
Drug: Oral trimegestone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trimegestone, 0.25 mg/day
Trial: 9391999
Drug: Oral trimegestone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trimegestone, 0.50 mg/day